Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001214659-23-007572 0001753085 XXXXXXXX LIVE 23 Common Stock, par value $0.0001 per share 11/25/2025 false 0001527728 29350E203 Lunai Bioworks Inc. 2080 Century Park East Suite 906 Los Angeles CA 90067 William Anderson Wittekind (424) 235-1810 8581 Santa Monica Blvd. #317 West Hollywood CA 90069 Patrick T. McCloskey 646.970.0611 McCloskey Law PLLC 260 Madison Avenue, 15th Floor New York NY 10016 0001753085 N William Anderson Wittekind b OO N X1 560665.00 1252656.00 560665.00 1252656.00 1813321.00 N 6.8 IN (1) The number of shares disclosed in Rows 7 and 9 consist of (i) 326,576 shares owned by William Anderson Wittekind ("Wittekind"); (ii) 84,032 shares owned by Weird Science LLC ("Weird Science"); (iii) 63,393 shares owned by the William Anderson Wittekind 2020 Annuity Trust, a grantor retained annuity trust of which Wittekind is the sole trustee (the "Wittekind 2020 Annuity Trust"); (iv) 45,057 shares owned by the Dybul 2020 Angel Annuity Trust, a grantor retained trust of which Wittekind is the sole trustee (the "Dybul 2020 Annuity Trust"); (v) 5,000 shares owned by the Ty Mabry 2021 Annuity Trust, a grantor retained annuity trust of which Wittekind is sole trustee (the "Mabry 2021 Annuity Trust"); and (vi) 36,608 shares owned by the William Anderson Wittekind 2021 Annuity Trust, a grantor retained annuity trust of which Wittekind is the sole trustee (the "Wittekind 2021 Annuity Trust" and, together with the Wittekind 2020 Annuity Trust, the Dybul 2020 Annuity Trust and the Mabry 2021 Annuity Trust, the "Trusts"). In his capacity as the sole manager of Weird Science, Wittekind has sole voting and sole dispositive power over the shares owned by Weird Science. In his capacity as the sole trustee of the Trusts, Wittekind has sole voting power and sole dispositive power over the shares owned by the Trusts. (2) The number of shares disclosed in Rows 8 and 12 consists of (i) 8,813 shares owned by Wittekind and Serhat Gumrukcu, Wittekind's spouse ("Gumrukcu"), as joint tenants with a right of survivorship ("JTWROS") and (ii) 1,243,844 shares owned by Gumrukcu, of which Wittekind shares voting and dispositive power through a power of attorney dated June 24, 2022. Pursuant to an order of the United States District Court for the District of Vermont dated October 27, 2023, the 12,438,431 shares owned by Gumrukcu are subject to a writ of attachment to secure the plaintiffs' claim in The Estate of Gregory Davis et al. v. Serhat Daniel Gumrukcu (Civil Case No. 5:22-cv-123). (3) The percentage ownership disclosed in Row 13 is based upon the sum of (i) 23,432,391 shares outstanding as of November 10, 2025, as disclosed in the Issuer's Form 10-Q filed with the Commission on November 14, 2025 plus (ii) 3,133,333 shares sold by the Issuer according to the Form 8-K filed with the Commission on November 25, 2025. Common Stock, par value $0.0001 per share Lunai Bioworks Inc. 2080 Century Park East Suite 906 Los Angeles CA 90067 This Amendment No. 23 amends the Schedule 13D filed by Weird Science LLC, a California limited liability company ("Weird Science") and William Anderson Wittekind, a member and manager of Weird Science ("Wittekind") with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Lunai Bioworks Inc. (the "Issuer") received by Weird Science pursuant to that certain Agreement and Plan of Merger dated January 12, 2018 (the "Merger Agreement") by and among the Issuer (then known as DanDrit BioTech USA, Inc.), DanDrit Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Issuer ("Merger Sub"), Renovaro Biopharma, Inc., a Delaware corporation then known as Enochian Biopharma Inc. ("Target"), and Weird Science, in its capacity as the majority stockholder of the Target, as amended by Amendment Nos. 1 through 22 thereto. Wittekind is the sole reporting person under this Amendment No. 23 to Schedule 13D (the "Reporting Person"). Capitalized terms used but not defined in this Amendment No. 23 have the meanings given to such terms in the initial Schedule 13D, as amended by Amendment Nos. 1 through 22 thereto. On November 25, 2025 the Issuer filed a Form 8-K reporting that it had sold 3,133,333 shares of Common Stock. This Amendment No. 23 is being filed to report the change in the Reporting Person's beneficial ownership from 7.8% to 6.8%. The information in Items 7-11 and Item 13 of the Cover Page of this Amendment No. 23, including the accompany notes, is hereby incorporated by reference into this Item 5(a). The information in Items 7-11 and Item 13 of the Cover Page of this Amendment No. 23, including the accompany notes, is hereby incorporated by reference into this Item 5(b). Not Applicable Not applicable Not applicable Not Applicable. Not Applicable William Anderson Wittekind /s/ William Anderson Wittekind William Anderson Wittekind 11/28/2025